Clinical Trials Logo

Sarcomatous Mesothelioma clinical trials

View clinical trials related to Sarcomatous Mesothelioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01105390 Withdrawn - Clinical trials for Recurrent Malignant Mesothelioma

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Start date: April 2010
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving AMG 102 together with pemetrexed disodium and cisplatin works in treating patients with malignant pleural mesothelioma. Monoclonal antibodies, such as AMG 102, can block tumor growth in different ways. Some block the ability of tumor cells to grow or spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AMG 102 together with pemetrexed disodium and cisplatin may kill more tumor cells

NCT ID: NCT00365053 Completed - Clinical trials for Recurrent Malignant Mesothelioma

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Start date: June 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well PXD101 works as second-line therapy in treating patients with malignant mesothelioma of the chest that cannot be removed by surgery. PXD101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00309946 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Start date: December 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well cediranib maleate works in treating patients with malignant mesothelioma that cannot be removed by surgery. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

NCT ID: NCT00243074 Completed - Clinical trials for Recurrent Malignant Mesothelioma

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Start date: November 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is study how well AZD2171 works in treating patients with malignant pleural mesothelioma that cannot be removed by surgery. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

NCT ID: NCT00107432 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

Start date: October 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works in treating patients with malignant mesothelioma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00039182 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Start date: May 2002
Phase: Phase 2
Study type: Interventional

Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This phase II trial is studying how well erlotinib works in treating patients with malignant mesothelioma of the lung

NCT ID: NCT00027703 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Start date: October 2001
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is to see if combination chemotherapy works better with or without bevacizumab in treating patients who have malignant mesothelioma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. It is not yet known if combination chemotherapy works better with or without bevacizumab in treating malignant mesothelioma.

NCT ID: NCT00025207 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Gefitinib in Treating Patients With Malignant Mesothelioma

Start date: September 2001
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of gefitinib in treating patients who have malignant mesothelioma. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of malignant mesothelioma